TY - JOUR
AB - Drugs & Therapy Perspectives https://doi.org/10.1007/s40267-023-01017-w DRUG REAC TIONS AND INTER AC TIONS © Springer Nature Switzerland AG 2023 Table 1 contains an overview of first published case reports meetings, media releases, regulatory agency websites, and of adverse drug reactions identified in the international lit- bulletins from the National Centers that participate in the erature in recent weeks by Reactions Weekly, the Adis drug WHO International Drug Monitoring Programme. safety newsletter. Reactions Weekly provides summaries of adverse drug reaction news sourced from journals, scientific Table 1 First reports of adverse drug reactions Drug: event (all serious) Reference Gimeracil/oteracil/tegafur: papular CD30+ T-cell pseudolymphoma Tsutsui Y, et al. Papular CD30+ T-cell pseudolymphoma induced by S-1. J Derma tol. 2022; 49(2): e48-9 Olmesartan-medoxomil+omeprazole: drug-induced necrotising pan- Walker A, et al. A rare case of drug-induced necrotizing pancreatitis creatitis (first report with olmesartan-medoxomil) [abstract no. A48]. J Am Geria tr Soc. 2023; 71 (Suppl 1): S31 Risankizumab: antiphospholipid syndrome Pulla JC, et al. Cerebral vasculitis in a patient receiving risankizumab, an inhibitor of interleukin-23: first case report [abstract no. P12- 3.013]. Neuro logy. 2023; 100 (17 Suppl 2): 2331 Sirolimus: toxic optic neuropathy Pakravan P, et al. Sirolimus induced toxic optic neuropathy. Int Med Case Rep J. 2023; 16: 329- 32 Teriflunomide: teriflunomide-induced Raynaud's 
TI - First reports of adverse drug reactions
JO - Drugs & Therapy Perspectives
DO - 10.1007/s40267-023-01017-w
DA - 2023-09-01
UR - https://www.deepdyve.com/lp/springer-journals/first-reports-of-adverse-drug-reactions-4kPyA4Xj4n
SP - 330
EP - 330
VL - 39
IS - 9
DP - DeepDyve
ER -